Braveheart Bio, Inc.
BRVE
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B
$26.74
▲ +1.79%
P/E
—
Mkt Cap
$1.9B
52-Wk Range
$24.31–$32.00
52-Week Range
$24.31 - $32.00
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 48.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Hot
+48.6% over 3m
Quality
Mixed
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying BRVE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Dec 2, 2026
SEP 2, 2026
Reported EPS of $0.85 vs $2.69 consensus (-68.4% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-68.4%
Wall Street consensus
4 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Cantor Fitzgerald · Aug 31, 2026
vs Industry
How BRVE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.